Safety and Efficacy of 48 and 96 Weeks of Alendronate in Children and Adolescents With Perinatal Human Immunodeficiency Virus Infection and Low Bone Mineral Density for Age
- 15 March 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 72 (6), 1059-1063
- https://doi.org/10.1093/cid/ciaa861
Abstract
No safety concerns were identified in a randomized, crossover study of alendronate/placebo in youth with perinatal HIV-infection and low bone mineral density (BMD). BMD improved with 48 weeks of alendronate and continued to improve with an additional 48 weeks of therapy. Gains were largely maintained 48 weeks after stopping alendronate.Funding Information
- National Institutes of Health (UM1AI068632, UM1AI068616, UM1AI106716)
- National Institute of Child Health and Human Development (HHSN275201800001I)
This publication has 8 references indexed in Scilit:
- Alendronate Improves Bone Mineral Density in Children and Adolescents Perinatally Infected With Human Immunodeficiency Virus With Low Bone Mineral Density for AgeClinical Infectious Diseases, 2019
- Peak Bone Mass in Young HIV-Infected Patients Compared With Healthy ControlsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2014
- Lower peak bone mass and abnormal trabecular and cortical microarchitecture in young men infected with HIV early in lifeAIDS, 2014
- Bone mineral density in children and adolescents with perinatal HIV infectionAIDS, 2013
- Dual Energy X-Ray Absorptiometry Body Composition Reference Values from NHANESPLOS ONE, 2009
- Continuous antiretroviral therapy decreases bone mineral densityAIDS, 2009
- The Bone Mineral Density in Childhood Study: Bone Mineral Content and Density According to Age, Sex, and RaceJournal of Clinical Endocrinology & Metabolism, 2007
- The Safety and Efficacy of Tenofovir DF in Combination with Lamivudine and Efavirenz Through 6 Years in Antiretroviral-Naïve HIV-1—Infected PatientsHIV Research & Clinical Practice, 2007